Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health, Inc. (JAGX) has announced a webcast interview featuring CEO Lisa Conte and Dragon SPAC lead sponsor Josh Mailman on April 23, 2021, at 8:30 AM Eastern. The discussion will cover the business overview of Napo EU S.p.A., its wholly owned Italian subsidiary. The Company is seeking conditional marketing authorization from the European Medicines Agency for crofelemer to treat COVID-related diarrhea. Jaguar is focused on developing sustainable, plant-based pharmaceuticals for gastrointestinal distress.

Jaguar Health, Inc. (NASDAQ:JAGX) announced a webcast interview on April 23, 2021, at 8:30 AM Eastern, featuring CEO Lisa Conte, aimed at providing an overview of Napo EU S.p.A., its Italian subsidiary. The company has also launched a rebranded Napo EU website, showcasing a new logo and promising expanded content. Mytesi®, Jaguar's key product, is the only FDA-approved plant-based medication for noninfectious diarrhea in adults with HIV/AIDS. The company focuses on developing sustainable plant-based pharmaceuticals for gastrointestinal issues.

Jaguar Health (NASDAQ:JAGX) announced an upsizing of its at-the-market (ATM) financing program by $15.3 million on April 15, 2021. This increase aims to provide future funding, with the company stating it does not plan to issue shares immediately. The company is pursuing conditional marketing authorization for crofelemer for COVID-related diarrhea. Additionally, Jaguar is merging Napo EU with the Dragon SPAC, anticipated for mid-2021, which is expected to support clinical efforts related to diarrhea in cancer patients. An educational contest is also launching for HIV awareness.

Jaguar Health (NASDAQ:JAGX) announces the acceptance of an abstract related to cancer therapy-related diarrhea (CTD) for poster presentation at the 2021 ASCO Annual Meeting, scheduled for June 4-8, 2021. This abstract is from Napo Pharmaceuticals, a subsidiary of Jaguar. In total, three CTD-related abstracts have been accepted for the event. The ASCO meeting received over 5,400 submissions this year. The press release highlights the significance of addressing CTD, a common side effect of cancer therapies that can impact treatment adherence and patient outcomes.

Jaguar Health (NASDAQ:JAGX) announced an amendment to its equity purchase agreement with Oasis Capital, increasing the stock purchase price from $0.436 to $3.00 per share. This amendment allows Oasis to purchase up to $2.0 million of Jaguar common stock over a 36-month period. The new price reflects the stock's recent performance, providing Jaguar access to capital for working needs while focusing on becoming a cash flow positive business through its product, Mytesi. The company will also issue a warrant for 100,000 common shares to Oasis as part of this agreement.

Jaguar Health, Inc. (NASDAQ:JAGX) has promoted Carol Lizak to the role of chief financial officer. This decision reflects her significant contributions in finance and strategic planning since joining the company in May 2019. Lizak brings over 20 years of experience in financial roles across various companies, enhancing Jaguar's transition from an R&D focus to a commercial-stage entity. Jaguar specializes in plant-based, non-opioid medicines for gastrointestinal issues and is known for its Mytesi® product, which is FDA-approved for treating noninfectious diarrhea in adults with HIV/AIDS.

Jaguar Health, Inc. (NASDAQ:JAGX) announced employee inducement grants on March 26, 2021, allocating nonstatutory stock options totaling 2,000 to 35,000 shares to five new employees. The exercise price is set at $1.84 per share, reflecting the March 26 closing price. Vesting occurs over three years, with the first 25% vesting nine months post-hire. Grants were made to attract talent as per NASDAQ rules. Jaguar develops plant-based medicines focused on gastrointestinal conditions, notably offering Mytesi, an FDA-approved product for HIV/AIDS patients.

Jaguar Health reported strong financial results for 2020, with Mytesi net sales rising 64% to approximately $9.3 million and gross sales increasing 148% to around $20.4 million. Despite a 7% decline in total Mytesi unit sales volume, the company saw a 12% reduction in net loss, totaling $33.8 million. Operating expenses grew by 4% year-over-year, primarily due to a rise in inducement expenses. Jaguar's focus on R&D remains evident with expenses of $6.4 million, reflecting ongoing development of Mytesi indications.

Jaguar Health, Inc. (NASDAQ:JAGX) has announced its support for the selection of the investment bank and nominated advisor for the proposed merger of the Dragon SPAC with its Italian subsidiary, Napo EU. This merger is anticipated to list on AIM Italia. Additionally, Jaguar's subsidiary conducted a meeting with the EU regulatory authority regarding crofelemer for COVID-related diarrhea, indicating the presence of unmet medical needs in this domain. Regulatory approval would allow for a conditional marketing authorization, utilizing safety data from Napo's approved US NDA.